A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes
NCT ID: NCT00871936
Last Updated: 2023-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
82 participants
INTERVENTIONAL
2009-04-30
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus
NCT00519142
Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
NCT01819272
Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
NCT01708902
Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes
NCT00971243
Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917
NCT00290940
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. FPG after 12 weeks
3. Safety and tolerability
4. Plasma levels of SLx-4090
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
SLx-4090 in combination with Metformin
SLx-4090
SLx-4090
Metformin
2
Placebo
Placebo
matching tablets
Metformin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SLx-4090
SLx-4090
Placebo
matching tablets
Metformin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On a stable dose of metformin for at least 6 weeks
Exclusion Criteria
* Antidiabetic medication other than or in addition to metformin
* FPG \> 270 mg/dL
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Response Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hickory, North Carolina, United States
Winston-Salem, North Carolina, United States
Anaheim, California, United States
Burbank, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
West Palm Beach, Florida, United States
Addison, Illinois, United States
Auburn, Maine, United States
Charlotte, North Carolina, United States
Greenville, South Carolina, United States
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SLx-4090-09-07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.